Screening a low prevalence population for HIV-2 using a combination HIV-1/HIV-2 enzyme immunoassay and an immunofluorescence assay.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Screening a low prevalence population for HIV-2 using a combination HIV-1/HIV-2 enzyme immunoassay and an immunofluorescence assay.

Abstr Gen Meet Am Soc Microbiol. 1994;94:554 (abstract no. C-361). Unique Identifier : AIDSLINE ASM94/94313106
Zanto SN; Treichel LJ; Abbott DO; Montana Public Health Laboratory, Helena.

Abstract: The Montana Public Health Laboratory has conducted screening for HIV-1 since 1985, with an estimated prevalence of HIV infection of 0.06%. To evaluate test performance and to determine the feasibility of incorporating screening for HIV-2, 2000 random serum specimens received for routine screening were tested using both Genetic Systems HIV-1/HIV-2 EIA and Viral Testing Systems Fluorognost HIV-2 IFA kits. Of the 2000 specimens screened, 1949 specimens were negative in both the EIA and IFA test systems. Three specimens were repeatedly reactive by EIA, and negative by IFA. One specimen was positive in both the EIA and IFA test systems. Forty-seven (47) specimens were EIA non-reactive and IFA repeatedly indeterminate. In order to resolve HIV antibody status of the reactive serum specimens, additional testing was necessary on 4 of 2000 EIA specimens, and 48 of 2000 IFA specimens. The present HIV-2 IFA kit appears better suited for supplemental HIV-2 testing rather than screening low prevalence populations. The incorporation of routine HIV-2 screening into the HIV testing algorithms of low prevalence populations, although feasible, may not be an appropriate use of limited public health resources.

Keywords: Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL Comparative Study Fluorescent Antibody Technique Human HIV Antibodies/*BLOOD HIV Seronegativity HIV Seropositivity *HIV Seroprevalence HIV-1/ISOLATION & PURIF HIV-2/*ISOLATION & PURIF Immunoenzyme Techniques Mass Screening Montana/EPIDEMIOLOGY Random Allocation Reagent Kits, Diagnostic ABSTRACT
941030
M94A0848

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .